The Career Development Program supports young Investigators pursuing careers in translational lymphoma research and also supports established investigators who wish to refocus their work on lymphoma. This program supports two individuals per year and provides 1-2 years of support for each awardee. The program is co-ordinated by the Administrative Core with oversight from the Executive Committee and Advisory Board. The program has well-defined processes for candidate recruitment, and will continue its successful efforts to recruit women and minorities. Both MD and PhD trainees selected by this program will be able to take advantage of courses available through the Clinical Scientist Training Program at BCM and will have a strong group of mentors with broad translational expertiseOijr mentoring strategies enhance the training program by providing trainees with multiple mentors who possess complementary skills, and planning Individualized training schemes. Additionally, trainees have access to the SPORE cores (clinical research, biostatistics, cell processing and vector production) which provide them with unique expertise in cell and gene therapy and clinical research. In the last 4 years, 6 trainees have been supported by this program and all have subsequently obtained independent peer-reviewed funding;three are now Incorporated Into SPORE projects.

Public Health Relevance

The goal of this program is to provide training in translational research In lymphoma, thereby Increasing the number of well qualified and trained investigators jn basic science, population science and clinical research who will contribute to improving lymphoma treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-07
Application #
8547762
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$152,165
Indirect Cost
$66,821
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34
Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :
Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83
Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 126:2588-96
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31
Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4
Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1

Showing the most recent 10 out of 218 publications